LASSBio-1632 is a novel anti-asthmatic lead candidate that selectively inhibits PDE4A and PDE4D isoenzymes, leading to the suppression of airway hyper-reactivity (AHR) and TNF-alpha production in lung tissue. With high experimental BBB permeability, LASSBio-1632 (7j) efficiently crosses the blood-brain barrier through passive diffusion [1].
Molecular Weight:
392.43
Formula:
C18H20N2O6S
Target:
Others|||PDE
* VAT and and shipping costs not included. Errors and price changes excepted
